Reed Johnson Selected Research

Parkinson Disease (Parkinson's Disease)

6/2021	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
1/2020	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
1/2019	Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
1/2019	Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.
1/2019	Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.
3/2018	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.
1/2018	Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
1/2018	Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
1/2017	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
1/2017	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Reed Johnson Research Topics

Disease

11	Dyskinesias (Dyskinesia) 01/2022 - 01/2017
10	Parkinson Disease (Parkinson's Disease) 06/2021 - 01/2017
2	Infections 05/2014 - 01/2013
1	Bacterial Infections (Bacterial Infection) 11/2023
1	Multiple Sclerosis 01/2022
1	Coronavirus Infections 01/2020
1	Disease Progression 01/2019
1	Movement Disorders (Movement Disorder) 03/2018

Drug/Important Bio-Agent (IBA)

12	Amantadine (Aman)FDA LinkGeneric 01/2022 - 01/2017
7	Levodopa (L Dopa)FDA LinkGeneric 06/2021 - 01/2017
1	Copper Sulfate (Sulfate, Copper)FDA Link 11/2023
1	Streptomycin (Streptomycin Sulfate)FDA Link 11/2023
1	AerosolsIBA 01/2020
1	VaccinesIBA 05/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013
1	Chemokine ReceptorsIBA 01/2013
1	InterferonsIBA 01/2013

Therapy/Procedure

3	Therapeutics 01/2020 - 05/2014
1	Ambulatory Care (Outpatient Care) 01/2022
1	Activities of Daily Living (ADL) 01/2019
1	Duration of Therapy 01/2018
1	Drug Therapy (Chemotherapy) 01/2018